Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

First-in-Human Study of ABS-169 in Healthy Volunteers (PATH-169)

11 novembre 2026 aggiornato da: Aerys Biosciences

A Phase I, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABS-169 in Healthy Volunteers

This is the first study of ABS-169 in people. ABS-169 is an oral investigational medicine that blocks MD2-TLR4 signalling, a pathway involved in inflammation and scarring (fibrosis) of organs such as the heart. The study will test single doses of ABS-169 or placebo in healthy adult volunteers to find out how safe and well tolerated it is, how much of the medicine gets into the blood and how quickly it is removed, and whether taking it with a high-fat meal changes how it is absorbed. Up to 40 healthy adults aged 18 to 55 will take part at one study centre in Melbourne, Australia.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

ABS-169-001 is a single-site, randomised, double-blind, placebo-controlled, first-in-human study with 4 sequential single ascending dose (SAD) cohorts (25, 75, 150 and 200 mg, fasted) and one stand-alone food-effect cohort (25 mg, fed). Each cohort enrols 8 new participants randomised 6:2 to ABS-169 or matching placebo.

Each cohort starts with 2 sentinel participants (1 ABS-169, 1 placebo); the remaining 6 are dosed only after review of at least Day 2 safety data from the sentinels. Participants are screened from Day -28, admitted on Day -1, receive a single oral dose on Day 1, remain confined until Day 3, and return for an end-of-study visit on Day 7 (±1 day). Fasted cohorts fast for at least 10 hours before and 4 hours after dosing. In the food-effect cohort, participants eat a standard high-fat breakfast starting 30 minutes before dosing and finish it within 30 minutes.

Blood samples for ABS-169 and its metabolite dihydroartemisinin (DHA) are taken before dosing and at 5, 15 and 30 minutes and 1, 1.5, 2, 4, 8, 12 and 24 hours after dosing.

A Safety Review Committee reviews blinded safety data through Day 7 and blinded PK data to 24 hours before each dose escalation. Escalation requires evaluable data from at least 7 of 8 participants, including both sentinels. The projected mean exposure at the next dose must also stay within the exposure limit (Cmax 2,460 ng/mL; AUC 4,470 h·ng/mL), which is the exposure at the no-observed-adverse-effect level in the 28-day rat toxicology study. Intermediate or lower dose levels may be used, but the maximum dose will not exceed 200 mg without a protocol amendment.

Tipo di studio

Interventistico

Iscrizione (Stimato)

40

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

  • Nome: Nucleus Network recruitment team Recruiting Site
  • Numero di telefono: 1800 243 733

Luoghi di studio

    • Victoria
      • Melbourne, Victoria, Australia, 3004
        • Nucleus Network Pty Ltd
        • Contatto:
          • Ofer Gonen
        • Investigatore principale:
          • Ofer Gonen, MBBS

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 55 anni (Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Written informed consent given before any study-related activities, with understanding of the nature, purpose, risks and adverse effects of the study.
  2. Adult males and females, 18 to 55 years of age (inclusive) at Screening.
  3. Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2 at Screening.
  4. Medically healthy in the opinion of the PI or delegate, without clinically significant abnormalities, including: normal physical examination; systolic BP 90-140 mmHg and diastolic BP 40-90 mmHg; pulse rate 40-100 bpm; tympanic temperature 35.5-37.5°C; ECG without clinically significant abnormalities including QTcF <450 msec; respiration rate 10-22 breaths/min; SpO2 ≥95%; no clinically significant findings in clinical chemistry, haematology, coagulation and urinalysis.
  5. Female volunteers must agree not to donate ova until at least 35 days after dosing and must either be of non-childbearing potential (surgically sterilised at least 6 weeks before Screening, or postmenopausal with confirmatory FSH), or, if of childbearing potential, have negative pregnancy tests at Screening and Day -1, agree not to attempt pregnancy, and use adequate contraception (male partner condom plus a highly effective non-hormonal method) from one month before Screening until at least 35 days after dosing, unless exclusively in a same-sex relationship or abstinent as a committed lifestyle.
  6. Male volunteers must agree not to donate sperm until at least 95 days after dosing. With a female partner who could become pregnant, they must use a condom plus a highly effective method of contraception until at least 95 days after dosing. With a partner of non-childbearing potential or a same-sex partner, they must use a condom until at least 5 days after dosing.
  7. Suitable venous access for blood sampling.
  8. Willing and able to comply with all study assessments, schedule and restrictions.

Exclusion Criteria:

  1. Known hypersensitivity to the study drug or any of its ingredients.
  2. History of anaphylaxis or other significant allergy that would interfere with participation.
  3. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, psychiatric or neurological disease, including any clinically relevant acute illness within the past 3 months.
  4. Major surgery or hospitalisation within 3 months before Screening, minor surgery under local anaesthetic within 1 month before Screening, or surgery planned during the study.
  5. Malignant disease in the last 10 years (except surgically resected skin squamous or basal cell carcinoma).
  6. Clinically relevant immunosuppression, including immunodeficiency conditions.
  7. Risk factors for torsade de pointes (including family history of long QT syndrome or sudden cardiac death) or a known arrhythmia.
  8. Gastrointestinal, liver (including Gilbert's syndrome), kidney or other conditions known to interfere with drug absorption, distribution, metabolism or excretion.
  9. History of known or unexplained bleeding disorders, or positive faecal occult blood test at Screening.
  10. GGT, bilirubin, ALP, AST or ALT >1.5× ULN. ALP/ALT/AST elevations may be accepted at PI discretion if they are normal variants without clinical signs.
  11. Estimated creatinine clearance <60 mL/min (Cockcroft-Gault) or serum creatinine >1.5× ULN.
  12. QTcF >450 msec (males) or >470 msec (females) confirmed on repeat; history of hypokalaemia or family history of long QT syndrome; or use of QT/QTc-prolonging medicines.
  13. Within 48 hours before dosing: caffeine or other xanthine-containing food or drink; foods that induce or inhibit liver enzymes (e.g., grapefruit, pomegranate, mango, dragon fruit); alcohol; or other factors affecting drug ADME, such as strenuous exercise.
  14. History of, or positive Screening test for, HIV, hepatitis B surface antigen or hepatitis C antibodies.
  15. Positive drugs-of-abuse or alcohol breath test at Screening or Day -1 (positive cotinine at Screening is not exclusionary).
  16. Regular consumption of more than 10 standard drinks per week or more than 4 standard drinks on any one day.
  17. Smoking more than 5 cigarettes (or equivalent nicotine products) per week, or unwilling to abstain from 72 hours before Day -1 and throughout confinement.
  18. Females who are breastfeeding or plan to breastfeed from Screening until 3 months after dosing.
  19. Unable to swallow oral medication.
  20. Use of any prescription or over-the-counter medication, including herbal products, vitamins and hormone supplements, within 7 days or 5 half-lives (whichever is longer) before dosing. Exceptions: contraceptives, paracetamol up to 2 g/day and ibuprofen up to 1.2 g/day, each for no more than 3 consecutive days. Drugs with known risk of TdP are prohibited.
  21. Current infection requiring systemic antibiotic, antifungal, antiparasitic or antiviral medication within 10 days before dosing.
  22. Any vaccination within 30 days before Screening.
  23. Blood or plasma donation, or blood loss >500 mL, within 30 days before dosing, or blood transfusion within 1 year.
  24. Participation in a study of an investigational drug or device within 30 days or 5 half-lives (whichever is longer) before Screening.
  25. Any other condition or prior therapy that, in the PI's opinion, makes the volunteer unsuitable, including likely non-compliance.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Cohort A1: ABS-169 25 mg (fasted)

Single oral dose of ABS-169 25 mg on Day 1 after an overnight fast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Sperimentale: Cohort A2: ABS-169 75 mg (fasted)

Single oral dose of ABS-169 75 mg on Day 1 after an overnight fast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Sperimentale: Cohort A2 (FE): ABS-169 25 mg (fed)

Single oral dose of ABS-169 25 mg on Day 1 after a standard high-fat breakfast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Sperimentale: Cohort A3: ABS-169 150 mg (fasted)

Single oral dose of ABS-169 150 mg on Day 1 after an overnight fast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Sperimentale: Cohort A4: ABS-169 200 mg (fasted)

Single oral dose of ABS-169 200 mg on Day 1 after an overnight fast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Comparatore placebo: Placebo (pooled across cohorts)

Single oral dose of matching placebo on Day 1, fasted or fed according to cohort (n=2 per cohort, up to 10)

Matching oral capsule containing microcrystalline cellulose, single dose

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of participants with treatment-emergent adverse events (TEAEs)
Lasso di tempo: Day 1 (dosing) through Day 7 (plus or minus 1 day)

TEAEs, including serious AEs, by severity and relationship to study drug (MedDRA). AEs are recorded from signing of consent; TEAEs are those starting or worsening after dosing.

Day 1 (dosing) through Day 7 (plus or minus 1 day)
Number of participants with clinically significant abnormalities in vital signs, 12-lead ECGs, clinical laboratory tests or physical examination
Lasso di tempo: Baseline (Screening and Day -1) through Day 7 (plus or minus 1 day)

Vital signs: blood pressure, pulse rate, respiratory rate, temperature, SpO2. ECG: including QTcF. Laboratory: haematology, chemistry, coagulation, urinalysis. Clinical significance is judged by the investigator.

Baseline (Screening and Day -1) through Day 7 (plus or minus 1 day)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Maximum Observed Plasma Concentration (Cmax) of ABS-169
Lasso di tempo: Pre-dose through 24 hours post-dose

Cmax of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Time to Maximum Observed Plasma Concentration (Tmax) of ABS-169
Lasso di tempo: Pre-dose through 24 hours post-dose

Tmax of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of ABS-169
Lasso di tempo: Pre-dose through 24 hours post-dose

AUClast of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of ABS-169
Lasso di tempo: Pre-dose through 24 hours post-dose

AUCinf of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Terminal Elimination Half-life (t1/2) of ABS-169
Lasso di tempo: Pre-dose through 24 hours post-dose

t1/2 of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Apparent Oral Clearance (CL/F) of ABS-169
Lasso di tempo: Pre-dose through 24 hours post-dose

CL/F of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Apparent Volume of Distribution During the Terminal Phase (Vz/F) of ABS-169
Lasso di tempo: Pre-dose through 24 hours post-dose

Vz/F of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Dose Proportionality of ABS-169 Cmax
Lasso di tempo: Pre-dose through 24 hours post-dose

Slope estimate with 90% confidence interval from a power model of log-transformed Cmax versus log-transformed dose across 25 to 200 mg (fasted cohorts).

Pre-dose through 24 hours post-dose
Dose Proportionality of ABS-169 AUCinf
Lasso di tempo: Pre-dose through 24 hours post-dose

Slope estimate with 90% confidence interval from a power model of log-transformed AUCinf versus log-transformed dose across 25 to 200 mg (fasted cohorts).

Pre-dose through 24 hours post-dose
Effect of Food on ABS-169 Cmax
Lasso di tempo: Pre-dose through 24 hours post-dose

Geometric mean ratio (fed/fasted) with 90% confidence interval for Cmax, comparing 25 mg fed (Cohort A2-FE) with 25 mg fasted (Cohort A1), from a general linear model on log-transformed data.

Pre-dose through 24 hours post-dose
Effect of Food on ABS-169 AUCinf
Lasso di tempo: Pre-dose through 24 hours post-dose

Geometric mean ratio (fed/fasted) with 90% confidence interval for AUCinf, comparing 25 mg fed (Cohort A2-FE) with 25 mg fasted (Cohort A1), from a general linear model on log-transformed data.

Pre-dose through 24 hours post-dose

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Identification of ABS-169 Metabolites in Plasma
Lasso di tempo: Pre-dose through 24 hours post-dose

Qualitative identification of ABS-169 and its metabolite if significant.

Pre-dose through 24 hours post-dose

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Ofer Gonen, MBBS, Nucleus Network Pty Ltd.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 novembre 2026

Completamento primario (Stimato)

1 agosto 2027

Completamento dello studio (Stimato)

1 gennaio 2028

Date di iscrizione allo studio

Primo inviato

22 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

11 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • ABS-169-001
  • 2026-09-1741 (Altro identificatore: Bellberry Limited Human Research Ethics Committee (Bellberry Application No.))

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

"There is no plan to make individual participant data available. Summary results will be posted on ClinicalTrials.gov."

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .